Applied Dna Sciences (NASDAQ:BNBX – Get Free Report) and IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.
Profitability
This table compares Applied Dna Sciences and IDEAYA Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Applied Dna Sciences | -1,647.25% | -349.95% | -283.96% |
| IDEAYA Biosciences | -75.93% | -16.73% | -15.34% |
Analyst Ratings
This is a summary of recent recommendations and price targets for Applied Dna Sciences and IDEAYA Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Applied Dna Sciences | 1 | 0 | 0 | 0 | 1.00 |
| IDEAYA Biosciences | 1 | 1 | 13 | 0 | 2.80 |
Volatility and Risk
Applied Dna Sciences has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500.
Valuation and Earnings
This table compares Applied Dna Sciences and IDEAYA Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Applied Dna Sciences | $2.09 million | 0.44 | -$15.16 million | ($3.33) | -0.05 |
| IDEAYA Biosciences | $234.13 million | 14.49 | -$113.70 million | ($1.94) | -19.90 |
Applied Dna Sciences has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Applied Dna Sciences, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
22.2% of Applied Dna Sciences shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 6.1% of Applied Dna Sciences shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
IDEAYA Biosciences beats Applied Dna Sciences on 10 of the 14 factors compared between the two stocks.
About Applied Dna Sciences
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company’s supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Receive News & Ratings for Applied Dna Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Dna Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
